Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the launch of travoprost ophthalmic solution USP, 0.004% (ionic buffered solution). Glenmark’s travoprost ophthalmic solution USP, 0.004% is ...
Empyrean Therapeutics acquires TLR-2 antagonist molecule from Eos Therapies to advance and commercialize breakthrough cancer treatment: Boca Raton, Florida Wednesday, November 27, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback